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L E T T E R TO TH E ED I TOR
Living with HIV in the time of COVID‐19: A glimpse of hope
Dear Editor,
As at the time of writing, the global confirmed cases of coronavirus
disease (COVID‐19) stand at 5 075 181 with 330 981 deaths and
1 936 331 recoveries.1 According to the Center for Disease Control,
the aged and individuals with compromised immune systems due to
infections (ie, human immunodeficiency viruses [HIV], etc.) are at
higher risk of contracting COVID‐19. The risk of further complica-
tions due to SARS‐CoV‐2 infection is even higher for HIV‐infected
patients with low CD4 cell count, and not on antiretroviral regimens
(ARVs).2 This has created fear and panic among HIV patients globally,
especially those from low‐income countries. UNAIDS estimated that
about 37.9 million people are infected with HIV globally, with 1.1 and
7.7 million of these people living in the United States and South
Africa, respectively.3,4 HIV‐infected patients in the US, even before
the outbreak of the COVID‐19, had kept a stockpile of HIV
medications4 and even more so under the situation created by the
pandemic, as they have been urged by the CDC to have at least a
30‐day supply of their HIV medicines.2 In contrast, the COVID‐19
pandemic disrupted HIV treatment programs in South Africa and may
increase mortality as a result of health facilities being overwhelmed
with COVID‐19 patients. Similarly, 19% of HIV‐infected patients
were unable to get antiretroviral medications (ART) refills due to the
pandemic.5 According to reports, more than 100 Russian AIDS pre-
vention and control centers have been converted to COVID‐19
treatment centers.6 Similar conversions might have happened in
other countries, thus denying patients access to HIV medication and
therapies. An earlier report had predicted that the pandemic would
have adverse effects on health programs for HIV, Tuberculosis (TB),
and malaria in low and middle economies. The authors also men-
tioned that in high burden settings, HIV, TB, and malaria‐related
deaths over 5 years may increase up to 10%, 20%, and 36%, re-
spectively, compared to the case in the world without COVID‐19.7
Table 1 summarizes cases of coinfections of HIV and COVID‐19. The
first HIV/SARS‐Cov‐2 coinfection of COVID‐19 was diagnosed in
only one HIV patient in Wuhan, China.8 Benkovic et al9 subsequently
reported four cases of HIV and COVID‐19 coinfection in Long Island,
New York, USA. The HIV‐infected patients were on HIV medications,
and hence, had robust CD4 T cell counts. Among the four patients,
only one required hospitalization due to further complications from
influenza A. These incidents suggested that uncomplicated cases of
COVID‐19 in an HIV‐infected patient can be managed. Furthermore,
COVID‐19 has been described in five patients with HIV in Barcelona,
Spain, four of whom were on ART at the time of admission. Fever and
cough were the common symptoms, among others. Four of the pa-
tients responded well to treatment and have been discharged, except
one who required extracorporeal life support.10 Despite the high
prevalence of HIV infections in Thailand, no coinfection case had
been recorded.11 Therefore, HIV‐infected patients under anti‐HIV
therapy with no other complications from other infections stand a
chance of being cured of COVID‐19. The findings have restored a
hint of a smile on the faces of HIV‐infected patients who were
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TABLE 1 Cases of coinfection of HIV and COVID‐19 according to the literature
Study No. 1 2 3
Author/Country Zhu et al8/Wuhan,
China
Benkovic et al9/Long Island, NY, USA Blanco et al10/Barcelona, Spain
Number of cases 1 4 5
Sex/age P1‐Male (61) P1‐ Male (56); P2‐ Male (56) P1‐ Transgender (40); P2‐ Male (49)
P3‐ Male (62); P4‐ Male (56) P3‐ Male (29); P4‐ Male (40)
P5‐ Transgender (31)













P2‐ Abacavir, lamivudine, dolutegravirb
P3‐ Emtricitabine, tenofovir
alafenamide, dolutegravir




P4‐ Abacavir, lamivudine, dolutegravirab
P5‐ Nonec
HIV viral load at or before
admission (copies/mL)
NR P1‐ 54; P2‐ <20; P3‐ <20; P4‐ <20 P1‐ <50; P2‐ <50; P3‐ <50; P4‐ <50; P5‐
45 500
CD4 cell count (cells/μL) NR P1‐ 1206; P2‐ 794; P3‐ 1412; P4‐ 929 P1‐ 616; P2‐ 445; P3‐ 604; P4‐ 1140; P5‐ 13
Present symptoms P1‐ Fever, difficult
breathing
P1‐ Fatigue, anosmia, aguesia P1‐ Fever, cough, malaise, headache
P2‐ Fever, fatigue P2‐ Fever, cough
P3‐ Fever, cough, fatigue, diarrhea P3‐ Fever, cough, malaise, headache, dyspnea
P4‐ Cough, fever P4‐ Fever, cough, malaise, headache, dyspnea
P5‐ Fever, cough, dyspnea
Outcome after COVID‐19
medication
P1‐ Cured All patients have been discharged and
are recovering at home
P1‐ Cured; P2‐ still at hospital
P3‐ Cured; P4‐ cured; P5‐ cured
Abbreviations: NR, not reported; P1, patient 1; P2, patient 2; P3, patient 3; P4, patient 4; P5, patient 5.
aPatient was given antibiotics and other medications.
bPatients were given additional antiviral and antibiotic treatment.
cDiagnosed recently.
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